The National Academies: Advisers to the Nation on Science, Engineering, and Medicine
Current Operating Status

The National Academies Testimony before Congress

Public Laws Containing Studies for the National Academies

Briefings to Congress

Congressionally Mandated Reports

Policy Statements and Historical Documents

The OCGA staff

Request a Report (Congressional and Government Staff Only)

Mailing Address:
The Office of Congressional and Government Affairs
The Keck Center of the National Academies
Keck WS1008
500 Fifth Street, NW
Washington, DC 20001
Tel: (202) 334-1601
Fax: (202) 334-2419

Back to Main Page

Briefing Date:06/24/2013
Topic:The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research

Institute of Medicine
Board on Health Sciences Policy
Committee to Review the Clinical and Translational Science Awards Program
at the National Center for Advancing Translational Sciences


Congressional Briefings
Monday, June 24, 2013
2358-B Rayburn House Office Bldg. – 10:00 a.m.
125 Hart Senate Office Bldg. – 2:00 p.m.
Monday, July 1, 2013
731 Hart Senate Office Bldg. – 10:30 a.m.


The CTSA Program at NIH:
Opportunities for Advancing Clinical and Translational Research

In response to a request from Congress in P.L. 112-74, the Institute of Medicine (IOM) provided an independent appraisal of and advice on the National Institutes of Health (NIH) Clinical and Translational Science Awards (CTSA) Program as it has been implemented by the newly formed National Center for Advancing Translational Sciences (NCATS). The current mission of the CTSA program includes services and infrastructure support for the full continuum of clinical and translational research. The services provided by CTSAs have supported T1 through T4 research, with primary emphasis on support for human subjects research extending from first-in-man and proof-of-concept studies through efficacy and effectiveness studies, and including research on how to achieve community and patient engagement, implementation and dissemination sciences, and behavioral research.

The IOM committee reviewed existing evaluations and available stakeholder input on the program, and sought additional stakeholder input as needed. Based on this assessment, the committee provided recommendations on the appropriateness of the program’s current mission and overarching goals and whether changes are needed. This study explored the contributions of the CTSAs in accelerating the development of new therapeutics with consideration given to the role of the CTSA program in facilitating disease-specific research and pediatric research and in enhancing the integration of programs funded by the categorical NIH Institutes and Centers.

These briefings were for members of Congress and congressional staff only. The report was publicly released on June 25, 2013 and can be found, in its entirety, on the Web site of the National Academies Press.

RSS News Feed | Subscribe to e-newsletters | Feedback | Back to Top